[HTML][HTML] Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity
Z Yuan, G Syrkin, A Adem, R Geha, J Pastoriza… - Cancer gene …, 2013 - nature.com
In the current study, we examined whether the combination of tumor vasculature-targeted
gene therapy with adeno-associated virus bacteriophage-tumor necrosis factor-α (AAVP …
gene therapy with adeno-associated virus bacteriophage-tumor necrosis factor-α (AAVP …
[PDF][PDF] Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity
Z Yuan, G Syrkin, A Adem, R Geha… - Cancer Gene …, 2013 - researchgate.net
Systemically delivered therapies often have significant unwanted side effects because of
their indiscriminant activity on both neoplastic and normal tissue. Targeted therapy, whether …
their indiscriminant activity on both neoplastic and normal tissue. Targeted therapy, whether …
Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity
Z Yuan, G Syrkin, A Adem, R Geha… - Cancer gene …, 2013 - pubmed.ncbi.nlm.nih.gov
In the current study, we examined whether the combination of tumor vasculature-targeted
gene therapy with adeno-associated virus bacteriophage-tumor necrosis factor-α (AAVP …
gene therapy with adeno-associated virus bacteriophage-tumor necrosis factor-α (AAVP …
[HTML][HTML] Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity
Z Yuan, G Syrkin, A Adem, R Geha… - Cancer Gene …, 2013 - ncbi.nlm.nih.gov
In the current study, we examined whether the combination of tumor vasculature-targeted
gene therapy with adeno-associated virus bacteriophage-tumor necrosis factor-α (AAVP …
gene therapy with adeno-associated virus bacteriophage-tumor necrosis factor-α (AAVP …
Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity
Z Yuan, G Syrkin, A Adem, R Geha… - Cancer gene …, 2013 - einstein.elsevierpure.com
In the current study, we examined whether the combination of tumor vasculature-targeted
gene therapy with adeno-associated virus bacteriophage-tumor necrosis factor-α (AAVP …
gene therapy with adeno-associated virus bacteriophage-tumor necrosis factor-α (AAVP …
Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity.
Z Yuan, G Syrkin, A Adem, R Geha… - Cancer Gene …, 2013 - search.ebscohost.com
In the current study, we examined whether the combination of tumor vasculature-targeted
gene therapy with adeno-associated virus bacteriophage-tumor necrosis factor-α (AAVP …
gene therapy with adeno-associated virus bacteriophage-tumor necrosis factor-α (AAVP …
Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity.
Z Yuan, G Syrkin, A Adem, R Geha, J Pastoriza… - Cancer Gene …, 2012 - europepmc.org
In the current study, we examined whether the combination of tumor vasculature-targeted
gene therapy with adeno-associated virus bacteriophage-tumor necrosis factor-α (AAVP …
gene therapy with adeno-associated virus bacteriophage-tumor necrosis factor-α (AAVP …
[PDF][PDF] Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity
Z Yuan, G Syrkin, A Adem, R Geha… - Cancer Gene …, 2013 - cyberleninka.org
Systemically delivered therapies often have significant unwanted side effects because of
their indiscriminant activity on both neoplastic and normal tissue. Targeted therapy, whether …
their indiscriminant activity on both neoplastic and normal tissue. Targeted therapy, whether …
Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity
Z Yuan, G Syrkin, A Adem, R Geha… - Cancer gene …, 2013 - researchwithrutgers.com
In the current study, we examined whether the combination of tumor vasculature-targeted
gene therapy with adeno-associated virus bacteriophage-tumor necrosis factor-α (AAVP …
gene therapy with adeno-associated virus bacteriophage-tumor necrosis factor-α (AAVP …
Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity
Z Yuan, G Syrkin, A Adem, R Geha… - Cancer gene …, 2013 - mdanderson.elsevierpure.com
In the current study, we examined whether the combination of tumor vasculature-targeted
gene therapy with adeno-associated virus bacteriophage-tumor necrosis factor-α (AAVP …
gene therapy with adeno-associated virus bacteriophage-tumor necrosis factor-α (AAVP …